Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)
The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping Peptide) technology and its applications to develop therapeutic vaccines to treat cancer.
OVM’s lead cancer vaccine, OVM-200, is in Phase 1 clinical trials to treat ovarian, prostate and lung cancers.
Read the more about the competition from Globaltech IP: